CORT - Corcept Therapeutics Inc Stock Price, Fair Value and News

35.63USD+0.76 (+2.18%)Market Closed

Market Summary

USD35.63+0.76

Market Closed

2.18%

CORT Alerts

3 major insider sales recently.

CORT Stock Price

View Fullscreen

CORT RSI Chart

CORT Valuation

Market Cap

3.7B

Price/Earnings (Trailing)

31.43

Price/Sales (Trailing)

7.09

EV/EBITDA

25.14

Price/Free Cashflow

29.71

CORT Price/Sales (Trailing)

CORT Profitability

Operating Margin

99.74%

EBT Margin

26.95%

Return on Equity

21.54%

Return on Assets

17.99%

Free Cashflow Yield

3.37%

CORT Fundamentals

CORT Revenue

Revenue (TTM)

523.5M

Rev. Growth (Yr)

38.95%

Rev. Growth (Qtr)

8.42%

CORT Earnings

Earnings (TTM)

118.0M

Earnings Growth (Yr)

74.83%

Earnings Growth (Qtr)

-11.46%

Breaking Down CORT Revenue

Last 7 days

5.2%

Last 30 days

12.8%

Last 90 days

56.3%

Trailing 12 Months

42.4%

How does CORT drawdown profile look like?

CORT Financial Health

Current Ratio

5.18

CORT Investor Care

Shares Dilution (1Y)

2.49%

Diluted EPS (TTM)

1.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	523.5M	0	0	0
2023	413.8M	428.2M	450.0M	482.4M
2022	380.2M	392.0M	397.6M	401.9M
2021	340.1M	343.1M	352.9M	366.0M
2020	334.9M	351.2M	356.0M	353.9M
2019	258.4M	268.4M	285.4M	306.5M
2018	189.3M	216.0M	237.7M	251.2M
2017	92.9M	108.7M	129.7M	159.2M
2016	56.2M	64.0M	72.5M	81.3M
2015	32.2M	38.4M	44.3M	50.3M
2014	13.0M	17.0M	21.7M	26.6M
2013	5.0M	6.0M	7.6M	10.4M
2012	2.4M	2.7M	3.0M	3.3M
2011	0	0	1.8M	2.1M
2010	0	566.0K	1.0M	1.5M
2009	0	0	0	101.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CEO	Dr. Joseph K. Belanoff M.D.
WEBSITE	corcept.com
INDUSTRY	Biotechnology
EMPLOYEES	299

Corcept Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Corcept Therapeutics Inc? What does CORT stand for in stocks?

CORT is the stock ticker symbol of Corcept Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corcept Therapeutics Inc (CORT)?

As of Fri Jul 26 2024, market cap of Corcept Therapeutics Inc is 3.71 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CORT stock?

You can check CORT's fair value in chart for subscribers.

Is Corcept Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CORT is over valued or under valued. Whether Corcept Therapeutics Inc is cheap or expensive depends on the assumptions which impact Corcept Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CORT.

What is Corcept Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, CORT's PE ratio (Price to Earnings) is 31.43 and Price to Sales (PS) ratio is 7.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CORT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Corcept Therapeutics Inc's stock?

In the past 10 years, Corcept Therapeutics Inc has provided 0.308 (multiply by 100 for percentage) rate of return.